Better Buy: Biogen vs. Amgen
If there were a hall of fame for biotech stocks, Biogen (NASDAQ: BIIB) and Amgen (NASDAQ: AMGN) would be in it. Biogen made its mark with multiple powerful multiple sclerosis (MS) drugs that fueled its remarkable rise. Amgen was one of the first biotechs on the scene back in the early 1980s and has reeled off a string of blockbuster drugs targeting a range of diseases.
But both Biogen and Amgen find themselves in a much different position than they've been accustomed to in the past. The big biotechs face significant challenges. Which is the better choice to survive and thrive in the future? Here's how Biogen and Amgen stack up against each other on several key fronts.
Image source: Getty Images.
Source Fool.com
